

# Randomized controlled trial of the Ampcare Effective Swallowing Protocol for persistent dysphagia post stroke

Dr Sue Pownall<sup>1</sup>, Lise Sproson<sup>1, 2</sup>, Professor Pam Enderby<sup>3</sup> and Dr Jenny Freeman<sup>3</sup>

<sup>1</sup> Sheffield Teaching Hospitals NHS Foundation Trust. <sup>2</sup>NIHR Devices for Dignity Healthcare Technology Co-operative. <sup>3</sup> School of Health & Related Research, University of Sheffield.

## Background

- Usual care for dysphagia post stroke has previously tended to focus on management of symptoms, rather than rehabilitation of swallow function
- More recently, a growing body of research is emerging to investigate potential new treatments. This has included electrical stimulation, however early research findings yielded conflicting results.
- This study therefore answers the call (NICE 2014) for more robust research in this area, in order to help inform clinical practice.

## Method

This Portfolio Randomized Controlled Pilot Study recruited 30 patients with post stroke dysphagia of >1 month duration.

It compared 2 groups:

- the control group, who received usual dysphagia care and
- the intervention group, who received treatment using the Ampcare ESP™ (Effective Swallowing Protocol) for 30 minutes each weekday, for a total of 20 sessions.



Ampcare electrodes in situ



AMPcare neck brace

The Ampcare ESP™ protocol uses;

- a new electrode shape, placed submentally in order to target the suprahyoid muscles
- electrical stimulation is used in combination with simultaneous laryngeal exercises
- a new, specially designed neck brace, in order to provide resistance during exercising


## Outcome measurement

Data was collected at 3 points: baseline, after treatment and one month later. The outcome measures included:

- FOIS (Functional Oral Intake Scale)
- Rosenbek Penetration Aspiration Scale (blinded assessment made during Videofluoroscopy)
- SWAL-QOL (Quality of Life in swallowing disorders)



Participants in the intervention group also complete a treatment tolerability questionnaire about their experience of the intervention.

## Results





FOIS Scale:

Level 1: Nothing by mouth. Level 2: Tube dependent with minimal attempts of food or liquid. Level 3: Tube dependent with consistent oral intake of food or liquid. Level 4: Total oral diet of a single consistency. Level 5: Total oral diet with multiple consistencies, but requiring special preparation or compensations. Level 6: Total oral diet with multiple consistencies without special preparation, but with specific food limitations. Level 7: Total oral diet with no restrictions.



Rosenbek Scale:

Score 8: Contrast passes glottis; visible subglottic residue; absent patient response. Score 7: Contrast passes glottis; visible subglottic residue despite patient response. Score 6: Contrast passes glottis; no subglottic residue visible. Score 5: Contrast contacts vocal folds; visible residue remains. Score 4: Contrast contacts vocal folds; no residue. Score 3: Contrast remains above the vocal folds; visible residue remains. Score 2: Contrast enters the airway, remains above the vocal folds; no residue. Score 1: Contrast does not enter the airway.



### Patient feedback:

"I feel better at swallowing – no problems swallowing at all now."

"I thought the treatment was very good and I would recommend it to anybody."

"I've enjoyed taking part. It's given me a positive feeling about my swallow."

### Carer feedback:

"He can drive short distances now without having to pull over to use the pot [to expectorate secretions] and he sleeps through the night now without waking up coughing."

"She's definitely not coughing anywhere near as much now."

## Conclusions

The intervention group achieved greater improvements in swallow function (compared to the usual care group) as measured by:

- range of oral intake (FOIS)
- reduction in aspiration and/or penetration with diet (Rosenbek)
- Quality of Life (SWAL-QOL)

A greater proportion of the intervention group made improvement (compared to the usual care group), on FOIS, Rosenbek and SWAL-QOL measures.

There have been no adverse events during 294 treatment sessions.

This supports the findings of a previous feasibility study in 2011.

The pilot study findings are promising and justify progression to a fully powered trial.

Correspondence to  
[Lise.Sproson@nhs.net](mailto:Lise.Sproson@nhs.net)

## Acknowledgement

We gratefully acknowledge funding for this study from: Sheffield Teaching Hospitals NHS Foundation Trust; Ampcare LLC; NIHR Devices for Dignity HTC; Collaboration for Leadership in Applied Health Research (South Yorkshire) and Royal College of Nursing (Lady Foley Award)

Sheffield Teaching Hospitals NHS  
NHS Foundation Trust



NHS  
National Institute for Health Research

NIHR CLAHRC  
for South Yorkshire

